AbbVie

Current directors and officers who also hold a role at another S&P 500 company.

• Roxanne S. AustinCRWD · DirectorVZ · Director
• Brett J. HartUAL · Officer
• Frederick H. WaddellIBM · Director
• Jennifer L. DavisPG · CEO
• Robert J. AlpernABT · Director
• Thomas J. FalkLMT · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Nov 2, 2026

   Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie.

   Read the 8-K filing
2. Oct 15, 2026

   Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc. Dr. Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie. The Board affirmatively determined that Dr. Carethers is an “independent director” under each of the standards set forth in section 303A.02 of the New York Stock Exchange Listed Company Manual and AbbVie’s Governance Guidelines and Director Independence Guidelines. Dr.

   Read the 8-K filing
3. May 13, 2025

   On May 9, 2025, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from fourteen directors to fifteen directors and appointed Thomas J. Falk as a Class III director. Mr. Falk was previously the Chairman and Chief Executive Officer of Kimberly-Clark Corporation. Mr. Falk has been appointed to the Audit Committee. The Board affirmatively determined that Mr. Falk is an “independent director” under each of the standards set forth in section 303A.02 of the New York Stock Exchange Listed Company Manual and AbbVie’s governance guidelines and director independence guidelines. Mr. Falk will be entitled to compensation as an independent director as disclosed in Exhibit 10.5 to AbbVie’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025.

   Read the 8-K filing
4. Feb 14, 2025

   Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On February 13, 2025, the Board of Directors (the “Board”) of AbbVie Inc. (the “Company”) unanimously elected Robert A. Michael to succeed Richard A. Gonzalez as the Company’s Chairman, effective July 1, 2025. Mr. Gonzalez, who has served as Chairman since the Company’s formation in 2013, will retire from the Board, effective July 1, 2025. Mr. Michael is the Company’s current Chief Executive Officer, as well as a director on the Board. On February 13, 2025, Glenn F. Tilton informed the Company of his decision to retire as a director, effective July 1, 2025 .

   Read the 8-K filing
5. Dec 13, 2024

   On December 11, 2024, Kevin K. Buckbee, Senior Vice President, Controller, informed AbbVie that he plans to retire from the Controller role effective March 1, 2025. David R. Purdue, 47, has been appointed Senior Vice President, Controller effective March 1, 2025 (the “Effective Date”). Mr. Purdue has been AbbVie’s Vice President, Controller, Commercial Operations since 2022. Mr. Purdue previously served as AbbVie’s Vice President, Treasurer; Vice President, Financial Planning and Analysis; and Vice President, Finance Integration Lead, among other finance organization roles at AbbVie and Abbott Laboratories, AbbVie’s former parent company. Mr. Purdue joined Abbott Laboratories in 2003. As of the Effective Date, Mr. Purdue’s annual base salary will be $550,000. Mr.

   Read the 8-K filing
6. May 8, 2024

   On February 20, 2024, AbbVie Inc. (“AbbVie”) filed a Form 8-K to announce that the Board of Directors (the “Board”) selected Robert A. Michael to succeed Richard A. Gonzalez as AbbVie’s Chief Executive Officer (CEO), effective July 1, 2024 (the “Effective Date”). Upon the Effective Date, Mr. Michael will become a member of the Board as a Class II director and Mr. Gonzalez will become Executive Chairman of the Board. On May 2, 2024, the Board approved Mr. Michael's new compensation package as CEO, as of the Effective Date, as follows: · Mr. Michael will receive an annual base salary of $1,700,000. · Mr. Michael will continue to be eligible to participate in AbbVie’s Performance Incentive Plan or any successor annual bonus plan with a target bonus equal to 150% of his base salary, subject to the attainment of one or more pre-established performance targets. Mr.

   Read the 8-K filing
7. Feb 20, 2024

   Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. On February 14, 2024, the Board of Directors (the “Board”) of AbbVie Inc. (the “Company”) unanimously selected Robert A. Michael to succeed Richard A. Gonzalez as the Company’s Chief Executive Officer (CEO). Mr. Gonzalez, who has served as CEO since the company’s formation in 2013, will retire from the role of CEO and become Executive Chairman of the Board of Directors, effective July 1, 2024. The Board also appointed Mr. Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024. Mr. Michael is currently AbbVie’s President and Chief Operating Officer. Mr.

   Read the 8-K filing
8. Oct 12, 2023

   On October 11, 2023, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from eleven directors to thirteen directors and appointed Jennifer Davis as a Class II director and Susan Quaggin as a Class III director. Ms. Davis currently serves as Chief Executive Officer, Health Care at Procter & Gamble. Dr. Quaggin currently serves as the Irving S. Cutter Professor and Chair of Medicine at Northwestern University Feinberg School of Medicine. Ms. Davis has been appointed to the Nominations and Governance Committee, and Dr. Quaggin has been appointed to the Public Policy and Sustainability Committee. The Board affirmatively determined that each of Ms. Davis and Dr.

   Read the 8-K filing
9. Jun 29, 2023

   Appointment of Certain Officers. Effective June 29, 2023, Robert A. Michael has been appointed President and Chief Operating Officer. Mr. Michael will continue to oversee AbbVie’s global commercial and financial operations. He will also be responsible for operations, human resources, business development and corporate strategy.

   Read the 8-K filing
10. Nov 29, 2022

    Scott T. Reents, Senior Vice President, Chief Financial Officer, has been appointed Executive Vice President, Chief Financial Officer, effective immediately. On November 28, 2022, Brian L. Durkin, Vice President, Controller, informed AbbVie that he plans to retire from the Controller role effective March 1, 2023. Kevin K. Buckbee, 57, has been appointed Senior Vice President, Controller effective March 1, 2023. Mr. Buckbee has been AbbVie’s Vice President and Controller, Global Commercial Operations since January 2016. Mr. Buckbee previously served as AbbVie’s Vice President and Controller, US Commercial Operations from AbbVie’s separation from Abbott Laboratories in 2013 until December 2015. Mr. Buckbee joined Abbott Laboratories in 1991 and held several positions in the finance organization.

    Read the 8-K filing
11. Oct 17, 2022

    Laura J. Schumacher, Vice Chairman, External Affairs and Chief Legal Officer, informed AbbVie that she plans to retire from the company after a period of transition. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

    Read the 8-K filing
12. Oct 14, 2022

    On October 12, 2022, the Board of Directors (the “Board”) of AbbVie Inc. (the “Company) adopted the Severance Agreement Policy (the “Policy”). The Policy provides that the Company will not create or renew any severance or termination agreement with any executive officer that provides for cash severance exceeding 2.99 times the sum of the executive officer’s base salary plus non-equity incentive plan bonus (as the bonus calculation is further detailed in the agreements regarding change in control), without ratification from a majority of votes cast by the Company’s stockholders. Also, on October 12, 2022, the Board approved changes to the Company’s form of change in control agreement (the “CIC Agreement”) to be entered into with each named executive officer (“NEO”). The Company expects to enter into each CIC Agreement with its NEOs on January 1, 2023.

    Read the 8-K filing
13. Jun 28, 2022

    Robert A. Michael, 51, has been appointed Vice Chairman and President, effective June 23, 2022. Mr. Michael has been AbbVie’s Vice Chairman, Finance and Commercial Operations and Chief Financial Officer since December 2021. Mr. Michael previously served as AbbVie’s Executive Vice President, Chief Financial Officer from October 2018 to December 2021, as AbbVie’s Vice President, Controller from March 2017 until October 2018, as Vice President, Treasurer from 2015 to 2016, and as Vice President, Controller, Commercial Operations from 2013 to 2015. Mr. Michael joined Abbott Laboratories in 1993 and held numerous positions in the finance organization. Scott T. Reents, 55, has been appointed Senior Vice President, Chief Financial Officer, effective June 23, 2022. Mr.

    Read the 8-K filing
14. Apr 13, 2022

    On April 8, 2022, Michael E Severino informed AbbVie that he will be departing as AbbVie’s Vice Chairman and President, effective May 31, 2022. He will be joining a bioplatform innovation company as CEO-Partner and as CEO of one of its companies.

    Read the 8-K filing
15. Mar 4, 2022

    On February 28, 2022, Edward M. Liddy informed AbbVie Inc. of his decision to retire as a director as of the 2022 annual shareholders meeting in May.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.